Carl Zeiss Meditec AG 2025 SR
The report details the Carl Zeiss Meditec Group's sustainability performance for the 2024/25 fiscal year, focusing on environmental protection, employee responsibility, and product safety. The company reported a significant reduction in market-based Scope 2 emissions through the procurement of renewable energy and power purchase agreements. It also disclosed its Scope 3 emissions for the first time, totaling 308,521 t CO2e. The group maintained high standards in corporate governance, achieving a 33.3% female representation on its Supervisory Board. Furthermore, the report outlines the company's alignment with the EU Taxonomy Regulation, identifying taxonomy-eligible activities in its core medical technology business.
Company: Carl Zeiss Meditec AG
Sector: Health Care
Country: Germany
Year: 2025
Type: SR
Pages: 32
Carl Zeiss Meditec AG
Non-Financial Report
The report details the Carl Zeiss Meditec Group's sustainability performance for the 2024/25 fiscal year, focusing on environmental protection, employee responsibility, and product safety. The company reported a significant reduction in market-based Scope 2 emissions through the procurement of renewable energy and power purchase agreements. It also disclosed its Scope 3 emissions for the first time, totaling 308,521 t CO2e. The group maintained high standards in corporate governance, achieving a 33.3% female representation on its Supervisory Board. Furthermore, the report outlines the company's alignment with the EU Taxonomy Regulation, identifying taxonomy-eligible activities in its core medical technology business.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Oct 1, 2023 - Sep 30, 2024
Fiscal Year
2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Women on Board
Employees